Radiopharm Theranostics Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported net loss was AUD 30.34 million. Basic loss per share from continuing operations was AUD 0.1674.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.04 AUD | +11.11% | -13.04% | -45.95% |
Feb. 29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
Feb. 29 | Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.95% | 11.95M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- RAD Stock
- News Radiopharm Theranostics Limited
- Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2022